生血宁片治疗血液透析患者肾性贫血的临床观察  

作　　者：张颖兰[1] 李小军[1] 胡琼丹[1] 许艳文[1] 张琼[1] 

机构地区：[1]泸州医学院附属中医院肾内科,四川泸州646000

出　　处：《大家健康（学术版）》2012年第18期45-47,共3页

摘　　要：目的比较生血宁片和右旋糖苷铁两种口服铁剂,在治疗伴有缺铁的血液透析患者肾性贫血的有效性和安全性。方法选择2011年4月至2012年4月间68例维持性血液透析贫血患者,随机分为生血宁片组和右旋糖苷铁组,试验组36例:生血宁片组,1.0gtid;对照组32例:右旋糖苷铁,50mgtid,观察期为12周。同时两组患者均使用基因重组人促红细胞生成素,按100～120U/(kg.周),分2次皮下注射或静脉注射,治疗期间调整EPO的用量维持Hb在100-120g/L。结果治疗前两组各项指标无明显差异,治疗后两组患者的血红蛋白、红细胞压积、血清铁蛋白较治疗前均显著上升,且两组患者升高的幅度相比,生血宁组升高的幅度更显著。治疗结束时,两组患者不良反应方面的差异无统计学意义。结论两种口服铁剂均能有效地纠正血液透析患者的铁缺乏及贫血状况;生血宁片组的作用更显著,且还具备降低患者促红细胞生成素使用量的作用。Objective To determine and compare the efficacy and safety of Shengxuening Tablet with Iron Dextran Oral Solution in rHuEPO-treated maintenance hemodialysis renal anemia patients with iron deficiency.Methods We chose 68 maintenance hemodialysis patients with iron deficiency were randomly assigned to two groups:Treatment group:oral Shengxuening Tablet,1g/tid;Control group:oral Iron Dextran 50mg/tid;for 12 weeks.EPO use: use the EPO in two groups at the same time.Subcutaneous or intravenous EPO 100～150IU.kg-1 week-1. During the therapy session,regulate the dose of EPO,to hold the Hb retain at 100~120 g/L.Results At the 12th week, the Hb ,HCT and SF levels in both groups significantly higher than prior treatment (P<0.05) ,however,the Hb,HCT and SF in Shengxuening tablet group was markedly higher than that in Control group.The Shengxuening tablet group patients' average of EPO weekly were lower than that in Control group(P<0.05)at the end.Conclusion The Shengxuening Tablet is effective and safe in maintenance hemodialysis renal anemia patients with iron deficiency,and this treatment may induce Hb level to rise faster with less adverse event than Iron Dextran Oral Solution,and the other more ,use the Shengxuening Tablet and EPO at the same time, it can reduce the dose of EPO .

关 键 词：生血宁片 右旋糖酐铁 维持性血透患者 肾性贫血 

分 类 号：R692.5[医药卫生—泌尿科学]